Hopital Prive D Antony
- Address
- lock Available on a paid plan
Diseases [C] - Bacterial Infections and Mycoses [C01]
The oncology unit at Hopital Prive D Antony integrates infection control research to protect patients undergoing cancer therapy, focusing on preventing and treating bacterial and fungal complications.
- Antibiotic stewardship in chemotherapy patients
- Prophylactic antifungal strategies
- Management of opportunistic infections during immunosuppression
These initiatives aim to enhance treatment tolerance and lower infection‑related interruptions in ongoing trials.
Diseases [C] - Digestive System Diseases [C06]
Clinical investigations target malignancies of the lower gastrointestinal tract, especially locally advanced anal squamous cell carcinoma, evaluating combined chemotherapy and radiotherapy approaches.
- Induction chemotherapy with modified DCF
- Standard chemoradiotherapy versus intensified regimens
- Two‑year disease‑free survival outcomes
The goal is to determine whether intensified treatment improves long‑term control while maintaining safety for patients.
Diseases [C] - Hemic and Lymphatic Diseases [C15]
The site conducts trials on B‑cell lymphomas, including follicular lymphoma and marginal zone lymphoma, comparing novel targeted combinations with established chemo‑immunotherapy.
- Zanubrutinib plus obinutuzumab versus lenalidomide‑rituximab
- Zanubrutinib plus rituximab versus lenalidomide‑rituximab
- Assessment of response rates and safety profiles
These studies seek to improve outcomes for patients with relapsed or refractory disease and expand therapeutic options.
Diseases [C] - Immune System Diseases [C20]
Research at the center evaluates next‑generation immunomodulators for chronic inflammatory skin conditions such as moderate to severe atopic dermatitis and hidradenitis suppurativa.
- Upadacitinib in adolescents and adults
- Spesolimab for hidradenitis suppurativa
- Povorcitinib efficacy in hidradenitis suppurativa
The objective is to demonstrate that these agents can provide durable symptom relief for patients who have exhausted conventional therapies.
Diseases [C] - Skin and Connective Tissue Diseases [C17]
A series of trials focus on severe dermatologic disorders, including prurigo nodularis, moderate to severe plaque psoriasis, and atopic dermatitis, testing topical and systemic interventions.
- Ruxolitinib cream for prurigo nodularis
- JNJ‑77242113 for plaque psoriasis
- Rocatinlimab combined with topical corticosteroids for atopic dermatitis
These programs aim to validate new treatment options that reduce skin inflammation and improve quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 68 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 68 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +13 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital Prive D Antony
lock Showing 1 of 51 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi-center, open-label, single-arm study to evaluate the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia (ITP) who failed first-line treatment | Sanofi-Aventis Recherche & Developpement | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 68 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 6 | Unknown | 2024-02-26 | 2025-08-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.